Hims & Hers and a peptide academy met White House reviewers before release, and the Partnership for Safe Medicines has petitioned the FDA to block it.
Recap by typeshit. Full story at The American Journal of Managed Care.
AP sources say FDA scientists opposed the HHS draft telling the agency not to act against pharmacies compounding six wellness peptides. Comments are open for two weeks.
Law firm Frier Levitt reads the rule as single-ingredient only, so the popular blend stays out. Public Citizen and ex-FDA official Janet Woodcock voice safety concerns.
Six peptides can now be compounded under strict conditions, but HHS itself says that proves nothing on safety, and research-use-only sellers stay outside the policy.
Compounders get a pass on BPC-157, TB-500 and four others if they meet sourcing and reporting rules. The Alliance for Pharmacy Compounding cheers it, while Public Citizen calls it reckless.
Lilly shares jumped 6% to a record high Thursday after earnings beat expectations, with weight loss drug sales leading the way.
He shares a short clip on why he started a GLP-1 and what it has been like, and points to a longer YouTube video that goes deeper.
Loading…